Literature summary extracted from

Landau, Z.; Novotny, M.J.; Preston, G.M.; Wright, K.; Freeman, T.; Dai, H.; Thompson, J.; Oates, P.J.; Calle, R.A.
Pharmacokinetics, pharmacodynamics, tolerability, and safety of a novel sorbitol dehydrogenase inhibitor in healthy participants (2010), J. Clin. Pharmacol., 50, 521-530.

Inhibitors

EC Number	Inhibitors	Comment	Organism	Structure
1.1.1.14	CP-642,931	a potent and specific sorbitol dehydrogenase inhibitor, rmacokinetics, biomarker pharmacodynamics, and safety analysis, overview. The inhibitor is rapidly absorbed through the oral route and effectively inhibits SDH. However, the drug is not well tolerated due to adverse neuromuscular effects. The inhibitor alters the red blood cell sorbitol dehydrogenase activity after oral administration	Homo sapiens

Organism

EC Number	Organism	UniProt	Comment	Textmining
1.1.1.14	Homo sapiens	-	-	-

Source Tissue

EC Number	Source Tissue	Comment	Organism	Textmining
1.1.1.14	erythrocyte	-	Homo sapiens	-

Substrates and Products (Substrate)

EC Number	Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
1.1.1.14	D-sorbitol + NAD+	-	Homo sapiens	? + NADH + H+	-	?

Synonyms

EC Number	Synonyms	Comment	Organism
1.1.1.14	ADH	-	Homo sapiens
1.1.1.14	sorbitol dehydrogenase	-	Homo sapiens

Temperature Optimum [°C]

EC Number	Temperature Optimum [°C]	Temperature Optimum Maximum [°C]	Comment	Organism
1.1.1.14	37	-	assay at	Homo sapiens

pH Optimum

EC Number	pH Optimum Minimum	pH Optimum Maximum	Comment	Organism
1.1.1.14	9.5	-	assay at	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)